You are here: Industry Insights > Regeneron

News List

Regeneron forms consortium to advance human gene sequencing pharmaceutical-technology
January 11, 2018
Regeneron Pharmaceuticals has formed a pre-competitive consortium with AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen and Pfizer to accelerate its gene sequencing project.
Regeneron and ISA Enter Immuno-Oncology Collaboration contractpharma
December 19, 2017
The collaboration is to advance ISA101 in combination with cemiplimab
Regeneron, Decibel Therapeutics collaborate over hearing loss and tinnitus therapeutics pharmaasia
December 08, 2017
Regeneron, Decibel Therapeutics collaborate over hearing loss and tinnitus therapeutics
Regeneron forced to drop Eylea combo, advantage Novartis pharmafile
November 28, 2017
Novartis released Phase 3 data on its leading candidate for wet age-related macular degeneration (AMD) drug and it caused a bit of a splash, as it compared strongly to Regeneron’s Eylea.
Regeneron Gets OK for Huge Expansion in Greenburgh, New York biospace
November 17, 2017
Regeneron is one step closer to its massive expansion plans for Greenburgh, N.Y., a town a few miles from the company headquarters in Tarrytown
Aimmune Therapeutics to collaborate with Sanofi/Regeneron biospectrumasia
October 18, 2017
The three companies are planning a 2018 midstage test of AR101 with adjunctive dupilumab in peanut-allergic patients
Sanofi and Regeneron’s projected blockbuster gains EU approval pharmafile
September 29, 2017
Sanofi and Regeneron have big hopes for their treatment Dupixent, and it has taken an important step towards reaching the blockbuster sales pinned to it with an approval in the EU.
Sanofi/Regeneron new asthma data bolstered by potential indications pharmafile
September 14, 2017
Sanofi and Regeneron’s Dupixent is predicted to grow to be one of the largest selling drugs in the industry but the expectation has heaped pressure onto every release of data the companies release.
Dupixent severe asthma results should propel Sanofi, Regeneron drug to billions more in sales fiercepharma
September 12, 2017
Dupixent, the Sanofi and Regeneron drug already on a blockbuster arc in atopic dermatitis, has returned significant results in patients with severe asthma
Regeneron, Sanofi Announce Positive Dupilumab Topline Results September 12, 2017
Regeneron and Sanofi announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page